Lumiere Therapeutics Raises Over RMB 100 Million to Advance Epigenetic Editing Therapies
Lumiere Therapeutics has raised more than RMB 100 million (approximately $14 million) in a Pre-A financing round, giving the Chinese gene-editing company fresh capital to push its epigenetic editing programs toward the clinic. The financing was co-led by…
Clover Biopharma’s RSV-hMPV-PIV3 Combination Vaccines Deliver Encouraging Phase 2 Results in Older Adults
Clover Biopharmaceuticals has reported positive preliminary Phase 2 data for SCB-1022 and SCB-1033, two next-generation combination respiratory vaccines designed to protect older adults against multiple major respiratory viruses with a single shot. The…
ApicHope’s AR882 Beats Febuxostat in China Phase 3 Gout Trial, Meeting Primary Endpoint
China’s ApicHope Pharmaceutical Group has reported positive topline results from a Phase 3 clinical trial of AR882 (pozdeutinurad), its next-generation URAT1 inhibitor for gout, showing statistically significant superiority over febuxostat in lowering…
China NMPA Clears Five Novel Drugs and Two New Indications in September Approval Wave
China’s National Medical Products Administration (NMPA) delivered another busy round of regulatory decisions in early September 2026, clearing a group of innovative therapies spanning oncology, infectious disease, cardiovascular medicine, hematology and…
Kelun-Biotech Biopharma
Innovative ADCs and Drug Conjugates for Patients Worldwide
CStone Pharmaceuticals
Building Globally Competitive Innovative Medicines
Livzon/Kanova’s Lecankitug Gets China Approval After Beating Secukinumab in Phase 3 Psoriasis Trial
China’s National Medical Products Administration (NMPA) has approved lecankitug (LZM012/XKH004), an IL-17A/IL-17F-targeting monoclonal antibody jointly developed by Livzon Pharmaceutical Group and Beijing Kanova Biopharmaceutical, for the treatment of…
AusperBio Raises $120 Million Series C to Advance AHB-137 Toward Hepatitis B Functional Cure and Commercialization
AusperBio has raised $120 million in Series C financing to advance its lead chronic hepatitis B therapy AHB-137 through Phase III development and prepare for potential commercialization, while expanding a next-generation pipeline of siRNA and combination…
Haisco Pharmaceutical Group
From Chinese Specialty Pharma to Global Innovative Drug Developer
Haisco Strikes $1.5 Billion NewCo Deal with Sentivera for Type 2 Inflammation Asset
Chinese drugmaker Haisco Pharmaceutical Group has struck another billion-dollar cross-border transaction, licensing ex-Greater China rights to a preclinical immunology asset to newly formed U.S. biotech Sentivera in a deal potentially worth more than…